TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from EUDA Health Holdings ( (EUDA) ) is now available.
On August 28, 2025, EUDA Health Holdings Limited announced the signing of a Letter of Intent to potentially acquire Chemokine Pte Ltd, a biotech company specializing in molecular supplements and gene modulating formulations. This acquisition could enhance EUDA’s market position by expanding its product offerings with Chemokine’s innovative health supplement, Euda Helixé, which focuses on energy, immune resilience, and cellular health. The exclusivity period for this potential acquisition is set for at least 120 days, during which Chemokine will not engage in similar discussions with other entities.
The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.
More about EUDA Health Holdings
EUDA Health Holdings Limited is a Singapore-based leading non-invasive healthcare provider in Asia, focusing on markets in Singapore, Malaysia, and China. The company aims to lead in non-invasive and preventive healthcare, particularly in the longevity sector, addressing the healthcare needs of a rapidly aging population in the region. EUDA also operates a property management business in Singapore.
Average Trading Volume: 81,148
Technical Sentiment Signal: Sell
Current Market Cap: $83.6M
Learn more about EUDA stock on TipRanks’ Stock Analysis page.